Workstream Type: Informing Dialogue

  • A $475,000 price tag for a new cancer drug: crazy or meh?

  • US Drug Prices And R&D, Take 2: A Reply To Grabowski And Manning, And To Light

  • Baseball Illuminates the Problem with U.S. Drug Pricing

    Baseball Illuminates the Problem with U.S. Drug Pricing

  • DPL and Collaborators to Publish Drug Pricing Primer Series

  • Is Outcomes-Based Contracting Worth It?

  • Copay Assistance: Doing More Harm Than Good?

  • A Q&A with Peter Bach

  • Expensive Oral Agents Responsible for Cost Shifting in Cancer

  • The Insurance Companies’ Latest Target: Specialty Drugs

  • Dr Steve Miller Highlights the Importance of Working Closely With Oncologists